(VIANEWS) – Another day of trading has ended and here’s today’s list of stocks that have had significant trading activity in the US session.

The three biggest winners today are Baudax Bio, Bellerophon Therapeutics, and CleanSpark.

The three biggest losers today are Canopy Growth, Brilliant Acquisition Corporation, and Aspen Group.

Winners today

1. Baudax Bio (BXRX) – 22.22%

Baudax Bio, Inc., a pharmaceutical company, develops and commercializes products for hospital and other acute care related settings. The company offers ANJESO (meloxicam) injection for the management of moderate to severe pain, alone or in combination with other non-NSAID analgesics. It also develops BX1000, an intermediate-acting neuromuscular blocking agent (NMB) that is in phase II clinical trial; BX2000, an ultra- short acting NMB, which is in phase I clinical trial, as well as a proprietary blockade reversal agent; and BX3000, a NMB reversal agent that is in preclinical studies. Baudax Bio, Inc. was incorporated in 2019 and is based in Malvern, Pennsylvania.

NASDAQ ended the session with Baudax Bio jumping 22.22% to $0.03 on Thursday while NASDAQ rose 1.38% to $14,733.96.

Earnings Per Share

As for profitability, Baudax Bio has a trailing twelve months EPS of $-94.13.

More news about Baudax Bio.

2. Bellerophon Therapeutics (BLPH) – 15.85%

Bellerophon Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its primary product is INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension. The company engages in the development of INOpulse, which is in Phase 3 clinical trial for the treatment of pulmonary hypertension associated with fibrotic interstitial lung disease; which has completed Phase 2a clinical trial for pulmonary hypertension associated with chronic obstructive pulmonary disease; and that has completed Phase 2 dose escalation stage for pulmonary hypertension associated with sarcoidosis, as well as for chronic thromboembolic pulmonary hypertension and pulmonary hypertension associated with pulmonary edema from high altitude sickness. The company was formerly known as Ikaria Development LLC and changed its name to Bellerophon Therapeutics, Inc. in January 2014. Bellerophon Therapeutics, Inc. was founded in 2009 and is headquartered in Warren, New Jersey.

NASDAQ ended the session with Bellerophon Therapeutics rising 15.85% to $0.04 on Thursday, following the last session’s upward trend. NASDAQ rose 1.38% to $14,733.96, after four consecutive sessions in a row of gains, on what was an all-around up trend exchanging session today.

Earnings Per Share

As for profitability, Bellerophon Therapeutics has a trailing twelve months EPS of $-0.89.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -165.96%.

More news about Bellerophon Therapeutics.

3. CleanSpark (CLSK) – 15.78%

CleanSpark, Inc. engages in the mining of bitcoin operations. It also provides data center services, including rack space, power, and equipment; and various cloud services, such as virtual, virtual storage, and data backup services. The company was formerly known as Stratean Inc. and changed its name to CleanSpark, Inc. in November 2016. CleanSpark, Inc. was incorporated in 1987 and is headquartered in Henderson, Nevada.

NASDAQ ended the session with CleanSpark rising 15.78% to $10.16 on Thursday while NASDAQ rose 1.38% to $14,733.96.

Earnings Per Share

As for profitability, CleanSpark has a trailing twelve months EPS of $-1.29.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -24.45%.

More news about CleanSpark.

4. Avenue Therapeutics (ATXI) – 13.24%

Avenue Therapeutics, Inc., a specialty pharmaceutical company, acquires, licenses, develops, and commercializes products primarily for use in the acute/intensive care hospital setting. Its product candidate is intravenous Tramadol, which is in Phase III clinical trials to treat moderate to moderately severe post-operative pain. The company was incorporated in 2015 and is based in New York, New York.

NASDAQ ended the session with Avenue Therapeutics jumping 13.24% to $0.15 on Thursday while NASDAQ jumped 1.38% to $14,733.96.

Earnings Per Share

As for profitability, Avenue Therapeutics has a trailing twelve months EPS of $-2.62.

More news about Avenue Therapeutics.

5. Zai Lab (ZLAB) – 11.48%

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience primarily in Mainland China and Hong Kong. Its commercial products include Zejula, a once-daily small-molecule poly polymerase 1/2 inhibitor; Optune, a device that delivers tumor treating fields; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; and Qinlock to treat gastrointestinal stromal tumors. The company also develops Odronextamab to treat follicular lymphoma, diffuse large B-cell lymphoma, and other B-celllymphomas; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Margetuximab for the treatment of breast and gastroesophageal cancers; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, pancreatic cancer, and other solid tumors; and Bemarituzumab to treat gastric and gastroesophageal junction cancer. In addition, it develops Zipalertinib for the treatment of patients with EGFR exon 20 insertion NSCLC; Elzovantinib, an orally bioavailable multi-targeted kinase inhibitor; ZL-2313, an investigational oral EGFR inhibitor; ZL-1211, a humanized IgG1 monoclonal antibody that targets CLDN18.2; ZL-1218 is humanized IgG1 monoclonal antibody to induce potent antibody-dependent cellular cytotoxicity activity that enables NK cell-mediated killing of CCR8-expressing T-regs; Efgartigimod to reduce disease-causing immunoglobulin G antibodies; ZL-1102, a human nanobody targeting interleukin- 17A; Sulbactam/durlobactam for the treatment of serious infections caused by Acinetobacter; and KarXT for the treatment of psychiatric and neurological conditions. The company was incorporated in 2013 and is headquartered in Shanghai, China.

NASDAQ ended the session with Zai Lab rising 11.48% to $29.82 on Thursday, following the last session’s upward trend. NASDAQ rose 1.38% to $14,733.96, after four consecutive sessions in a row of gains, on what was an all-around positive trend trading session today.

Earnings Per Share

As for profitability, Zai Lab has a trailing twelve months EPS of $-3.1.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -30.29%.

Earnings Before Interest, Taxes, Depreciation, and Amortization

Zai Lab’s EBITDA is 7.01.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Zai Lab’s stock is considered to be overbought (>=80).

Volatility

Zai Lab’s last week, last month’s, and last quarter’s current intraday variation average was a negative 1.67%, a negative 0.09%, and a positive 2.54%.

Zai Lab’s highest amplitude of average volatility was 1.67% (last week), 2.23% (last month), and 2.54% (last quarter).

More news about Zai Lab.

6. Blue Bird Corporation (BLBD) – 10.45%

Blue Bird Corporation designs, engineers, manufactures, and sells school buses and related parts in the United States, Canada, and internationally. It operates through two segments, Bus and Parts. The company offers Type C, Type D, and specialty buses; and alternative fuel applications through its propane powered, gasoline powered, compressed natural gas powered, and electric powered school buses, as well as diesel engines. Blue Bird Corporation sells its products through a network of dealers, as well as directly to fleet operators, the United States government, and state governments; and maintains a parts distribution center. Blue Bird Corporation was formerly known as Hennessy Capital Acquisition Corp. The company was founded in 1927 and is headquartered in Macon, Georgia.

NASDAQ ended the session with Blue Bird Corporation rising 10.45% to $24.09 on Thursday, after five consecutive sessions in a row of gains. NASDAQ jumped 1.38% to $14,733.96, after four successive sessions in a row of gains, on what was an all-around positive trend trading session today.

Earnings Per Share

As for profitability, Blue Bird Corporation has a trailing twelve months EPS of $-0.58.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -110.39%.

Earnings Before Interest, Taxes, Depreciation, and Amortization

Blue Bird Corporation’s EBITDA is 0.73.

Growth Estimates Quarters

The company’s growth estimates for the current quarter and the next is 140% and 18.5%, respectively.

Volume

Today’s last reported volume for Blue Bird Corporation is 3297990 which is 1128.49% above its average volume of 268459.

Yearly Top and Bottom Value

Blue Bird Corporation’s stock is valued at $24.09 at 01:32 EST, way below its 52-week high of $28.80 and way higher than its 52-week low of $8.91.

More news about Blue Bird Corporation.

7. Vertex Pharmaceuticals (VRTX) – 10.22%

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO and SYMDEKO/SYMKEVI for people with CF with at least one F508del mutation for 6 years of age or older; ORKAMBI for CF homozygous F508del mutation for CF patients 2 year or older; and KALYDECO for the treatment of patients with 4 months or older who have CF with a mutation that is responsive to ivacaftor, and R117H mutation or one of certain gating mutations. The company's pipeline includes VX-522, a CF mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial; and VX-864 for treatment of AAT deficiency, which is in Phase 2 clinical trial. In addition, it provides VX-147 for the treatment of APOL1-mediated focal segmental glomerulosclerosis and co-morbidities, such as hypertension which is in single Phase 2/3; VX- 880, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-970, which is in Phase 2 clinical trial for the treatment of cancer; and VX-803 and VX-984 for treatment of cancer in Phase 1 clinical trial. Further, it sell the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies or pharmacy chains, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; Entrada Therapeutics, Inc.; Affinia Therapeutics; Arbor Biotechnologies, Inc.; Kymera Therapeutics, Inc.; Mammoth Biosciences, Inc.; Obsidian Therapeutics, Inc.; Verve Therapeutics; Skyhawk Therapeutics; and Ribometrix, Inc. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.

NASDAQ ended the session with Vertex Pharmaceuticals rising 10.22% to $394.29 on Thursday, after two sequential sessions in a row of gains. NASDAQ rose 1.38% to $14,733.96, after four successive sessions in a row of gains, on what was an all-around positive trend trading session today.

Earnings Per Share

As for profitability, Vertex Pharmaceuticals has a trailing twelve months EPS of $13.31.

PE Ratio

Vertex Pharmaceuticals has a trailing twelve months price to earnings ratio of 29.62. Meaning, the purchaser of the share is investing $29.62 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 23.49%.

More news about Vertex Pharmaceuticals.

8. Clearside Biomedical (CLSD) – 8.95%

Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase 1/2a clinical trial; and CLS-301, an integrin inhibitor suspension for the treatment of diabetic macular edema and macular degeneration. Clearside Biomedical, Inc. has a collaboration with Bausch Health, Arctic Vision, REGENXBIO, Inc., and Aura Biosciences. The company was incorporated in 2011 and is headquartered in Alpharetta, Georgia.

NASDAQ ended the session with Clearside Biomedical jumping 8.95% to $1.03 on Thursday while NASDAQ jumped 1.38% to $14,733.96.

Earnings Per Share

As for profitability, Clearside Biomedical has a trailing twelve months EPS of $-0.61.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -1310.02%.

Moving Average

Clearside Biomedical’s worth is way above its 50-day moving average of $0.92 and under its 200-day moving average of $1.04.

Yearly Top and Bottom Value

Clearside Biomedical’s stock is valued at $1.03 at 01:32 EST, way below its 52-week high of $1.85 and way above its 52-week low of $0.65.

Volume

Today’s last reported volume for Clearside Biomedical is 41347 which is 67.15% below its average volume of 125898.

More news about Clearside Biomedical.

9. Axcella Health (AXLA) – 8.35%

Axcella Health Inc. operates as a clinical stage biotechnology company in the United States. It treats complex diseases and enhances health using endogenous metabolic modulator compositions. The company's lead product candidates include AXA1665 for the treatment of overt hepatic encephalopathy; and AXA1125 for treating non-alcoholic steatohepatitis. It also develops AXA4010, a hematology product candidate; and AXA2678, a muscle product candidate. The company was formerly known as Newco LS16, Inc. and changed its name to Axcella Health Inc. in June 2016. Axcella Health Inc. was incorporated in 2008 and is based in Cambridge, Massachusetts.

NASDAQ ended the session with Axcella Health rising 8.35% to $0.96 on Thursday while NASDAQ rose 1.38% to $14,733.96.

Earnings Per Share

As for profitability, Axcella Health has a trailing twelve months EPS of $-18.25.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -1370.17%.

Yearly Top and Bottom Value

Axcella Health’s stock is valued at $0.96 at 01:32 EST, way under its 52-week high of $41.25 and way above its 52-week low of $0.81.

More news about Axcella Health.

10. Brookfield Residential Properties (BRP) – 8.3%

BRP Group, Inc. markets and sells insurance products and services in the United States. It operates through four segments: Middle Market, Specialty, MainStreet, and Medicare. The Middle Market segment provides commercial risk management, employee benefits solutions, and private risk management for mid-to-large size businesses and high net worth individuals, as well as its families. The Specialty segment delivers specialty insurers, professionals, individuals, and industry businesses the access to specialty markets, as well as capabilities and programs requiring underwriting and placement; and operates as a managing general agent of the Future platform, which delivers proprietary, technology-enabled insurance solutions. The MainStreet segment offers personal insurance, commercial insurance, and life and health solutions to individuals and businesses in its communities. The Medicare segment provides consultation for government assistance programs and solutions, including Medicare and Medicare Advantage to seniors and Medicare-eligible individuals through a network of primarily independent contractor agents. The company was founded in 2011 and is headquartered in Tampa, Florida.

NASDAQ ended the session with Brookfield Residential Properties jumping 8.3% to $21.00 on Thursday while NASDAQ jumped 1.38% to $14,733.96.

Earnings Per Share

As for profitability, Brookfield Residential Properties has a trailing twelve months EPS of $-1.79.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -16.8%.

Yearly Top and Bottom Value

Brookfield Residential Properties’s stock is valued at $21.00 at 01:32 EST, way below its 52-week high of $32.12 and way higher than its 52-week low of $17.33.

Volume

Today’s last reported volume for Brookfield Residential Properties is 767972 which is 58.23% above its average volume of 485330.

Revenue Growth

Year-on-year quarterly revenue growth grew by 18.1%, now sitting on 1.18B for the twelve trailing months.

More news about Brookfield Residential Properties.

Losers Today

1. Canopy Growth (CGC) – -25.18%

Canopy Growth Corporation, together with its subsidiaries, engages in the production, distribution, and sale of cannabis and hemp-based products for recreational and medical purposes primarily in Canada, the United States, and Germany. It operates through two segments, Global Cannabis and Other Consumer Products. The company's products include dried cannabis flower, extracts and concentrates, beverages, gummies, and vapes. It offers its products under the Tweed, 7ACRES, 7ACRES Craft Collective, DOJA, Ace Valley, Quatreau, Deep Space, First + Free, Surity Pro, Spectrum Therapeutics, Vert, Tokyo Smoke, Twd, Martha Stewart CBD, DNA Genetics, BioSteel, Storz & Bickel, This Works, HiWay, Simple Stash, Whisl, and Truverra brands. The company was formerly known as Tweed Marijuana Inc. and changed its name to Canopy Growth Corporation in September 2015. Canopy Growth Corporation was incorporated in 2009 and is headquartered in Smiths Falls, Canada.

NASDAQ ended the session with Canopy Growth falling 25.18% to $0.51 on Thursday while NASDAQ rose 1.38% to $14,733.96.

Earnings Per Share

As for profitability, Canopy Growth has a trailing twelve months EPS of $-1.55.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -99.66%.

Moving Average

Canopy Growth’s worth is way under its 50-day moving average of $0.63 and way below its 200-day moving average of $0.98.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Canopy Growth’s stock is considered to be overbought (>=80).

More news about Canopy Growth.

2. Brilliant Acquisition Corporation (BRLIW) – -20.34%

NASDAQ ended the session with Brilliant Acquisition Corporation dropping 20.34% to $0.05 on Thursday, after five consecutive sessions in a row of losses. NASDAQ rose 1.38% to $14,733.96, after four successive sessions in a row of gains, on what was an all-around up trend trading session today.

More news about Brilliant Acquisition Corporation.

3. Aspen Group (ASPU) – -10.88%

Aspen Group, Inc., an education technology company, provides online higher education services in the United States. The company offers baccalaureate, master's, and doctoral degree programs in nursing and health sciences, business and technology, arts and sciences, and education fields through Aspen University and United States University. As of April 30, 2022, it had 13,334 degree-seeking students enrolled. Aspen Group, Inc. was founded in 1987 and is based in New York, New York.

NASDAQ ended the session with Aspen Group falling 10.88% to $0.16 on Thursday, following the last session’s downward trend. NASDAQ jumped 1.38% to $14,733.96, after four sequential sessions in a row of gains, on what was an all-around up trend trading session today.

Earnings Per Share

As for profitability, Aspen Group has a trailing twelve months EPS of $-0.38.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -24.26%.

More news about Aspen Group.

4. Beyond Meat (BYND) – -9.11%

Beyond Meat, Inc. develops, manufactures, markets, and sells plant-based meat products in the United States and internationally. The company sells a range of plant-based meat products across the platforms of beef, pork, and poultry. It sells its products through grocery, mass merchandiser, club, convenience, and natural retailer channels, as well as various food-away-from-home channels, including restaurants, foodservice outlets, and schools. The company was formerly known as Savage River, Inc. and changed its name to Beyond Meat, Inc. in September 2018. Beyond Meat, Inc. was founded in 2009 and is headquartered in El Segundo, California.

NASDAQ ended the session with Beyond Meat dropping 9.11% to $9.59 on Thursday while NASDAQ jumped 1.38% to $14,733.96.

Earnings Per Share

As for profitability, Beyond Meat has a trailing twelve months EPS of $-3.89.

Volatility

Beyond Meat’s last week, last month’s, and last quarter’s current intraday variation average was 1.03%, 2.43%, and 4.04%.

Beyond Meat’s highest amplitude of average volatility was 5.20% (last week), 5.02% (last month), and 4.04% (last quarter).

Earnings Before Interest, Taxes, Depreciation, and Amortization

Beyond Meat’s EBITDA is 4.25.

More news about Beyond Meat.

5. Pfizer (PFE) – -7.7%

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Retacrit, Lorbrena, and Braftovi brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc., as well as strategic partnership with CSPC Pharmaceutical Group Limited to launch a local brand of the COVID-19 oral therapeutic treatment Nirmatrelvir/Ritonavir in China, and a collaboration with Carrick Therapeutics Limited. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

NYSE ended the session with Pfizer falling 7.7% to $26.38 on Thursday, after two consecutive sessions in a row of losses. NYSE jumped 1.55% to $16,539.02, after four consecutive sessions in a row of gains, on what was an all-around positive trend trading session today.

Earnings Per Share

As for profitability, Pfizer has a trailing twelve months EPS of $1.83.

PE Ratio

Pfizer has a trailing twelve months price to earnings ratio of 14.42. Meaning, the purchaser of the share is investing $14.42 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 11.06%.

Moving Average

Pfizer’s value is way under its 50-day moving average of $30.94 and way under its 200-day moving average of $36.02.

Revenue Growth

Year-on-year quarterly revenue growth declined by 41.6%, now sitting on 68.54B for the twelve trailing months.

Dividend Yield

As stated by Morningstar, Inc., the next dividend payment is on Nov 8, 2023, the estimated forward annual dividend rate is 1.64 and the estimated forward annual dividend yield is 5.7%.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Pfizer’s stock is considered to be overbought (>=80).

Previous days news about Pfizer

• : Pfizer expects to close seagen deal on Thursday, will create a new oncology division to incorporate company. According to MarketWatch on Tuesday, 12 December, "The company will create an end-to-end business organization called the Pfizer Oncology Division, which will combine certain commercial and R&D operations from both companies. "
• Pfizer shares down 8% as 2024 financial guidance disappoints wall street. According to MarketWatch on Wednesday, 13 December, "As it wrestles with reduced COVID sales expectations and acquires cancer-drug maker Seagen, Pfizer is expecting 2024 revenue to range from $58.5 billion to $61.5 billion, below the $62.6 billion FactSet consensus. ", "Products from the Seagen portfolio are expected to contribute $3.1 billion in 2024 revenues, Pfizer said. "

More news about Pfizer.

6. AYRO (AYRO) – -7.17%

Ayro, Inc. designs and manufactures light-duty, emissions-free electric vehicles for urban and community transport, local delivery, closed campus mobility, recreational, and government use. It offers AYRO 311, a 3-wheeled vehicle for professional and personal use; Club Car 411 for low-speed logistics and cargo services for campus; and AYRO 511 4×4 concepts. The company was formerly known as AEV Technologies, Inc. Ayro, Inc. was founded in 2017 and is headquartered in Round Rock, Texas.

NASDAQ ended the session with AYRO sliding 7.17% to $2.07 on Thursday, following the last session’s downward trend. NASDAQ rose 1.38% to $14,733.96, after four successive sessions in a row of gains, on what was an all-around up trend exchanging session today.

Earnings Per Share

As for profitability, AYRO has a trailing twelve months EPS of $-6.92.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -65.69%.

Yearly Top and Bottom Value

AYRO’s stock is valued at $2.07 at 01:32 EST, way below its 52-week high of $7.52 and way higher than its 52-week low of $1.47.

Growth Estimates Quarters

The company’s growth estimates for the present quarter and the next is a negative 6.7% and a negative 9.2%, respectively.

Moving Average

AYRO’s value is higher than its 50-day moving average of $1.88 and way under its 200-day moving average of $4.02.

More news about AYRO.

7. VerifyMe (VRME) – -6.92%

VerifyMe, Inc., together with its subsidiary, PeriShip Global, LLC, operates as a technology solutions provider that specializes in products to connect brands with consumers and providing brands with end-to-end logistics management for their products. The company operates through two segments, VerifyMe Solutions and PeriShip Global Solutions. The VerifyMe Solutions segment offers technology solutions to connect brands with consumers allowing brand owners to gather business intelligence while engaging directly with their consumers. Its solutions provide brand protection and supply chain functions, such as counterfeit prevention, traceability, consumer engagement solutions, and authentication for labels, packaging, and products, as well as tamper-proof labels. The PeriShip Global Solutions segment offers predictive analytics for optimizing delivery of time and temperature sensitive perishable products. This segment's products include PeriTrack customer dashboard, an integrated web portal tool gives its customers an in-depth look at their shipping activities based on real-time data. It also provides call center, pre-transit, post-delivery, and weather/traffic services. The company has a strategic partnership with INX International Ink Company. The company was formerly known as LaserLock Technologies, Inc. and changed its name to VerifyMe, Inc. in July 2015. VerifyMe, Inc. was incorporated in 1999 and is headquartered in Lake Mary, Florida.

NASDAQ ended the session with VerifyMe sliding 6.92% to $1.21 on Thursday, after three successive sessions in a row of gains. NASDAQ rose 1.38% to $14,733.96, after four successive sessions in a row of gains, on what was an all-around bullish trend trading session today.

Earnings Per Share

As for profitability, VerifyMe has a trailing twelve months EPS of $-0.29.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -26.16%.

Yearly Top and Bottom Value

VerifyMe’s stock is valued at $1.21 at 01:32 EST, way below its 52-week high of $2.27 and way higher than its 52-week low of $0.85.

Revenue Growth

Year-on-year quarterly revenue growth grew by 7.5%, now sitting on 26.3M for the twelve trailing months.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, VerifyMe’s stock is considered to be oversold (<=20).

More news about VerifyMe.

8. Southwest Airlines (LUV) – -6.37%

Southwest Airlines Co. operates as a passenger airline company that provide scheduled air transportation services in the United States and near-international markets. As of December 31, 2022, the company operated a total fleet of 770 Boeing 737 aircrafts; and served 121 destinations in 42 states, the District of Columbia, and the Commonwealth of Puerto Rico, as well as ten near-international countries, including Mexico, Jamaica, the Bahamas, Aruba, the Dominican Republic, Costa Rica, Belize, Cuba, the Cayman Islands, and Turks and Caicos. It also provides inflight entertainment portal and connectivity services on Wi-Fi enabled aircrafts; and Rapid Rewards loyalty program that enables program members to earn points for dollars spent on Southwest base fares. In addition, the company offers a suite of digital platforms to support customers' travel needs, including websites and apps; and SWABIZ, an online booking tool. Further, it provides ancillary services, such as Southwest's EarlyBird Check-In, upgraded boarding, and transportation of pets and unaccompanied minors. The company was incorporated in 1967 and is headquartered in Dallas, Texas.

NYSE ended the session with Southwest Airlines falling 6.37% to $28.38 on Thursday while NYSE jumped 1.55% to $16,539.02.

Earnings Per Share

As for profitability, Southwest Airlines has a trailing twelve months EPS of $0.81.

PE Ratio

Southwest Airlines has a trailing twelve months price to earnings ratio of 35.04. Meaning, the purchaser of the share is investing $35.04 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 4.52%.

Revenue Growth

Year-on-year quarterly revenue growth grew by 4.9%, now sitting on 25.44B for the twelve trailing months.

Sales Growth

Southwest Airlines’s sales growth is 8.7% for the present quarter and 8.2% for the next.

Moving Average

Southwest Airlines’s worth is way higher than its 50-day moving average of $25.10 and below its 200-day moving average of $30.28.

Previous days news about Southwest Airlines

• Southwest airlines (luv) rises higher than market: key facts. According to Zacks on Monday, 11 December, "On that day, Southwest Airlines is projected to report earnings of $0.14 per share, which would represent year-over-year growth of 136.84%. ", "In terms of valuation, Southwest Airlines is currently trading at a Forward P/E ratio of 20.92. "

More news about Southwest Airlines.

9. Brooge Energy Limited (BROGW) – -6.25%

Brooge Energy Limited, through its subsidiaries, provides oil storage and related services at the Port of Fujairah in the United Arab Emirates. It operates phase I and phase II facilities comprising 22 tanks with a capacity of approximately 1,001,388 cubic meters for offering storage, heating, and blending of fuel oil and clean petroleum products, including aviation fuel, gas oil, gasoline, marine gas oil, and naphtha. The company was formerly known as Brooge Holdings Limited and changed its name to Brooge Energy Limited in April 2020. Brooge Energy Limited was incorporated in 2019 and is headquartered in Dubai, the United Arab Emirates.

NASDAQ ended the session with Brooge Energy Limited dropping 6.25% to $0.02 on Thursday, after five sequential sessions in a row of losses. NASDAQ jumped 1.38% to $14,733.96, after four sequential sessions in a row of gains, on what was an all-around bullish trend exchanging session today.

Yearly Top and Bottom Value

Brooge Energy Limited ‘s stock is valued at $0.02 at 01:32 EST, higher than its 52-week high of $0.02.

Revenue Growth

Year-on-year quarterly revenue growth grew by 121.5%, now sitting on 116.05M for the twelve trailing months.

More news about Brooge Energy Limited .

10. Conifer Holdings (CNFR) – -6.15%

Conifer Holdings, Inc., an insurance holding company, engages in the sale of property and casualty insurance products. It offers insurance coverage in specialty commercial and personal product lines. The company underwrites various specialty insurance products, including property, general liability, liquor liability, automobile, and homeowners and dwelling policies. It serves the commercial insurance needs of owner-operated businesses in the markets, such as hospitality, which includes restaurants, bars, taverns, and bowling centers, as well as small grocery and convenience stores; artisan contractors comprising plumbers, painters, carpenters, electricians, and other independent contractors; and security service providers, including companies that provide security guard services, security alarm products and services, and private investigative services. The company also offers specialty homeowners insurance products, such as low- value dwelling insurance tailored for owners of lower valued homes in Illinois, Indiana, Louisiana, and Texas; and wholesale agency services comprising commercial and personal lines insurance products for its insurance company subsidiaries, as well as third party insurers. Conifer Holdings, Inc. markets and sells its insurance products through a network of approximately 4,900 independent agents in 50 states in the United States. The company was incorporated in 2009 and is headquartered in Troy, Michigan.

NASDAQ ended the session with Conifer Holdings sliding 6.15% to $1.22 on Thursday while NASDAQ jumped 1.38% to $14,733.96.

Earnings Per Share

As for profitability, Conifer Holdings has a trailing twelve months EPS of $-0.27.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -31%.

Sales Growth

Conifer Holdings’s sales growth is negative 27.1% for the ongoing quarter and negative 5.2% for the next.

Revenue Growth

Year-on-year quarterly revenue growth declined by 2.1%, now sitting on 103.79M for the twelve trailing months.

More news about Conifer Holdings.

Stay up to date with our winners and losers daily report